

BIOLIGHT LIFE SCIENCES LTD.

INTERIM CONSOLIDATED FINANCIAL STATEMENTS

AS OF MARCH 31, 2017

CONSOLIDATED BALANCE SHEETS

	March 31,		December 31,
	2017	2016	2016
	Unreview	Unaudited	Audited
	NIS in thousands		
ASSETS			
CURRENT ASSETS:			
Cash and cash equivalents	19,842	42,220	25,057
Short-term deposits	381	370	417
Trade receivables	111	380	648
Other accounts receivable	965	1,435	1,415
Inventories	2,812	952	2,494
	<u>24,111</u>	<u>45,357</u>	<u>30,031</u>
NON-CURRENT ASSETS:			
Leasing deposits	62	145	85
Property and equipment, net	1,154	887	1,287
Goodwill and intangible assets, net	3,910	6,810	3,910
	<u>5,126</u>	<u>7,842</u>	<u>5,282</u>
	<u><u>29,237</u></u>	<u><u>53,199</u></u>	<u><u>35,313</u></u>

CONSOLIDATED BALANCE SHEETS

	March 31,		December 31,
	2017	2016	2016
	Unreview	Unaudited	Audited
<u>NIS in thousands</u>			
LIABILITIES AND EQUITY			
CURRENT LIABILITIES:			
Trade payables	1,088	1,162	2,776
Other accounts payable	4,372	5,315	4,212
	<u>5,460</u>	<u>6,477</u>	<u>6,988</u>
NON-CURRENT LIABILITIES:			
Liability for grants	10,081	8,974	10,355
Excess of losses over investment in company accounted for at equity	42	68	66
Other long-term liabilities	1,494	683	1,494
	<u>11,617</u>	<u>9,725</u>	<u>11,915</u>
EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:			
Share capital, premium and reserves	243,142	243,542	242,331
Accumulated deficit	(235,853)	(218,068)	(231,490)
	<u>7,289</u>	<u>25,474</u>	<u>10,841</u>
Non-controlling interests	4,871	11,523	5,569
Total equity	<u>12,160</u>	<u>36,997</u>	<u>16,410</u>
	<u>29,237</u>	<u>53,199</u>	<u>35,313</u>

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

	Three months ended		Year ended
	March 31,		December 31,
	2017	2016	2016
	Unreview	Unaudited	Audited
	NIS in thousands (except per share data)		
Revenues	355	759	2,111
Cost of revenues	265	300	996
Gross profit	90	459	1,115
Research and development expenses, net	3,244	2,611	10,982
Selling and marketing expenses	1,321	1,336	5,132
General and administrative expenses	2,049	2,369	8,418
Other expenses, net	(241)	3,719	6,985
	6,373	10,035	31,517
Operating loss	6,283	9,576	30,402
Finance income	(34)	(4)	(1)
Finance expenses	1,156	1,414	2,837
Company's share of losses of company accounted for at equity	168	147	372
Net loss	7,573	11,133	33,610
Other comprehensive loss:			
Foreign currency translation adjustments	(13)	(4)	5
Total comprehensive loss	7,560	11,129	33,615
Total net loss attributable to:			
Equity holders of the Company	4,363	8,402	21,824
Non-controlling interests	3,210	2,731	11,786
	7,573	11,133	33,610
Total comprehensive loss attributable to:			
Equity holders of the Company	4,350	8,398	21,829
Non-controlling interests	3,210	2,731	11,786
	7,560	11,129	33,615
Loss per share attributable to equity holders of the Company (in NIS):			
Basic and diluted loss	1.67	3.22	8.37
Weighted number of shares used in the computation of loss per share	2,606,688	2,606,688	2,606,688

CONSOLIDATED STATEMENTS OF CASH FLOWS

	Three months ended		Year ended
	March 31,		December 31,
	2017	2016	2016
	Unreview	Unaudited	Audited
	NIS in thousands		
Net cash used in operating activities	<u>(7,152)</u>	<u>(8,063)</u>	<u>(26,942)</u>
Net cash used in investing activities	<u>(154)</u>	<u>(70)</u>	<u>(627)</u>
Net cash provided by financing activities	<u>3,224</u>	<u>893</u>	<u>2,554</u>